Critical residues involved in tau binding to fyn: Implications for tau phosphorylation in Alzheimer's disease

Acta Neuropathologica Communications

Volumn 4, Issue 1, 2016, Pages

  Lau, Dawn H W ^a   Hogseth, Marte ^a   Phillips, Emma C ^a   O'Neill, Michael J ^b   Pooler, Amy M ^a,c   Noble, Wendy ^a   Hanger, Diane P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Alzheimer's disease; Fyn; Phosphorylation; PXXP motif; SH3; Tau

Indexed keywords

MAPT PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN KINASE FYN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANIMAL; BRAIN; CHO CELL LINE; CRICETULUS; ESCHERICHIA COLI; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN MOTIF; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID MOTIFS; ANIMALS; BRAIN; CHO CELLS; CRICETULUS; ESCHERICHIA COLI; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN DOMAINS; PROTO-ONCOGENE PROTEINS C-FYN; TAU PROTEINS;

EID: 85006267095     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-016-0317-4     Document Type: Article

References (43)

1. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142(3):387-97. doi:10.1016/j.cell.2010.06.036.
2. Pooler AM, Noble W, Hanger DP. A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology. 2014;76:1-8. doi:10.1016/j.neuropharm.2013.09.018.
3. Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30(36):11938-50. doi:10.1523/jneurosci.2357-10.2010.
4. Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm J. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptordependent tau phosphorylation. J Biol Chem. 2012;287(38):32040-53. doi:10.1074/jbc.M112.401240.
5. Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci. 1998;111(21):3167-77.
6. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging. 2012;33(2):431.e427-38. doi:10.1016/j. neurobiolaging.2011.01.005.
7. Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, Perera T, Zvelebil M, Yang A, Sheppard PW, Varndell IM, Hanger DP, Anderton BH. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem. 2008;283(26):18177-86.
8. Cochran JN, Hall AM, Roberson ED. The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull. 2014;103:18-28. doi:10.1016/j. brainresbull.2013.12.004.
9. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene. 2004;23(48):7918-27. doi:10.1038/sj.onc.1208081.
10. Usardi A, Pooler AM, Seereeram A, Reynolds CH, Derkinderen P, Anderton B, Hanger DP, Noble W, Williamson R. Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J. 2011;278(16):2927-37. doi:10. 1111/j.1742-4658.2011.08218.x.
11. Cochran JN, Diggs PV, Nebane NM, Rasmussen L, White EL, Bostwick R, Maddry JA, Suto MJ, Roberson ED. AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease. J Biomol Screen. 2014;19(10):1338-49. doi:10.1177/1087057114547232.
12. Derkinderen P, Scales TM, Hanger DP, Leung KY, Byers HL, Ward MA, Lenz C, Price C, Bird IN, Perera T, Kellie S, Williamson R, Noble W, Van Etten RA, Leroy K, Brion JP, Reynolds CH, Anderton BH. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci. 2005;25(28):6584-93.
13. Burton EA, Hunter S, Wu SC, Anderson SM. Binding of src-like kinases to the beta-subunit of the interleukin-3 receptor. J Biol Chem. 1997;272(26):16189-95.
14. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-86.
15. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1(3):213-6.
16. Bhaskar K, Yen SH, Lee G. Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem. 2005;280(42):35119-25.
17. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15(3):112-9.
18. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271-8.
19. Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: A radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem. 1992;59:750-3.
20. Kurbatskaya K, Phillips EC, Croft CL, Dentoni G, Hughes MM, Wade MA, Al-Sarraj S, Troakes C, O'Neill MJ, Perez-Nievas BG, Hanger DP, Noble W. Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. Acta Neuropathol Commun. 2016;4:34. doi:10.1186/s40478-016-0299-2.
21. Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, Mandelkow E. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubulebinding region. EMBO J. 1992;11:1593-7.
22. Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM, Duara R, Graff-Radford NR, Dickson DW, Murray ME. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol. 2012;124(5):681-92. doi: 10.1007/s00401-012-1044-y.
23. Hasegawa M, Morishima-Kawashima M, Takio K, Suzuki M, Titani K, Ihara Y. Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J Biol Chem. 1992;267(24):17047-54.
24. Espinoza M, de Silva R, Dickson DW, Davies P. Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis. 2008;14(1):1-16.
25. Vingtdeux V, Davies P, Dickson DW, Marambaud P. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 2011;121(3):337-49. doi:10.1007/ s00401-010-0759-x.
26. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103(1):26-35.
27. Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem. 1992;267:564-9.
28. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913-7.
29. Ksiezak-Reding H, Binder LI, Yen SH. Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer's disease brains with Alz 50 and Tau-1. J Biol Chem. 1988;263:7948-53.
30. Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, van Dyck CH, Nygaard HB, Strittmatter SM. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015;77(6):953-71. doi:10.1002/ana.24394.
31. Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, MacDonald JF. Fyn, a potential target for Alzheimer's disease. J Alzheimers Dis. 2011;27(2):243-52. doi:10.3233/jad-2011-110353.
32. Nisbet RM, Polanco JC, Ittner LM, Gotz J. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol. 2015;129(2):207-20. doi:10.1007/ s00401-014-1371-2.
33. Ittner LM, Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12(2):65-72. doi:10.1038/nrn2967.
34. Attiori Essis S, Laurier-Laurin ME, Pepin E, Cyr M, Massicotte G. GluN2Bcontaining NMDA receptors are upregulated in plasma membranes by the sphingosine-1-phosphate analog FTY720P. Brain Res. 2015;1624:349-58. doi:10.1016/j.brainres.2015.07.055.
35. Tintori C, La Sala G, Vignaroli G, Botta L, Fallacara AL, Falchi F, Radi M, Zamperini C, Dreassi E, Dello Iacono L, Orioli D, Biamonti G, Garbelli M, Lossani A, Gasparrini F, Tuccinardi T, Laurenzana I, Angelucci A, Maga G, Schenone S, Brullo C, Musumeci F, Desogus A, Crespan E, Botta M. Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors. J Med Chem. 2015;58(11):4590-609. doi:10.1021/acs.jmedchem.5b00140.
36. Alexandropoulos K, Cheng G, Baltimore D. Proline-rich sequences that bind to Src homology 3 domains with individual specificities. Proc Natl Acad Sci U S A. 1995;92(8):3110-4.
37. Lim WA, Richards FM, Fox RO. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature. 1994; 372(6504):375-9. doi:10.1038/372375a0.
38. Feng S, Chen JK, Yu H, Simon JA, Schreiber SL. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3- ligand interactions. Science. 1994;266(5188):1241-7.
39. Mayer BJ. SH3 domains: complexity in moderation. J Cell Sci. 2001;114(Pt 7): 1253-63.
40. Zhao ZS, Manser E, Lim L. Interaction between PAK and nck: a template for Nck targets and role of PAK autophosphorylation. Mol Cell Biol. 2000;20(11): 3906-17.
41. Rickles RJ, Botfield MC, Zhou XM, Henry PA, Brugge JS, Zoller MJ. Phage display selection of ligand residues important for Src homology 3 domain binding specificity. Proc Natl Acad Sci U S A. 1995;92(24):10909-13.
42. Schneider A, Biernat J, von BM, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry (Mosc). 1999;38(12):3549-58.
43. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89(2):297-308.